Quantum Leap Healthcare Collaborative

Agent Information Sheet

Widely hailed as the future of phase II drug development, the adaptive I-SPY 2 platform trial has set a new benchmark for
Close
Close
I-SPY Trial Manuscript
<- Back to All Agents

veliparib

Trade Name:
ABT-888
Company:
Status:
Graduated
Treatment Protocol:
ABT-888 is a Polyadenosine Diphosphate Ribose Polymerase (PARP) inhibitor. Treatment with ABT-888 was given at 50 mg bid continuously combined with paclitaxel at 80 mg/m2 per week (for 12 weeks continuously) and carboplatin at an AUC 6 every 3 weeks for a total of 4 doses. ABT-888 is orally self-administered by the study participant. This was followed by 4 cycles of AC.
Date Entered I-SPY:
March 10, 2010
Date Left I-SPY:
July 10, 2012
No. Participants in Arm:
75
Graduating Subtypes:
HR- HER2- (Triple Negative)
Agent Description:

Veliparib (ABT-888) is a potential anti-cancer drug acting as a PARP inhibitor. It kills cancer cells by blocking a protein called PARP, thereby preventing the repair of DNA or genetic damage in cancer cells and possibly making them more susceptible to anticancer treatments. Veliparib may make whole brain radiation treatment work more effectively against brain metastases from NSCLC. It has been shown to potentiate the effects of many chemotherapeutics, and as such has been part of many combination clinical trials.

Notes:
Final pCR Probabilities:
Primary Manuscript:
Rugo HS, Olopade, OI, DeMichele A, et al.
Adaptive randomization of veliparib-carboplatin treatment in breast cancer
New Engl J Med
 
375
23-34
2016
abstractpdfview original